Plasma Cell Neoplasm – Drugs In Development, 2023

Powered by

Unlock hidden opportunities in the Pharmaceuticals industry

$2000
Buy Report

Published: January 03, 2024 Report Code: GDGMDHC23651IDB-L5

Select Item

Global Markets Direct’s, ‘Plasma Cell Neoplasm – Drugs In Development, 2023’, provides an overview of the Plasma Cell Neoplasm pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Plasma Cell Neoplasm, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Plasma Cell Neoplasm and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase

* Global Markets Direct, is a research brand owned and operated by GlobalData.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Plasma Cell Neoplasm

  • The report reviews pipeline therapeutics for Plasma Cell Neoplasm by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved Plasma Cell Neoplasm therapeutics and enlists all their major and minor projects

  • The report assesses Plasma Cell Neoplasm therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news related to pipeline therapeutics for Plasma Cell Neoplasm

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand important and diverse types of therapeutics under development for Plasma Cell Neoplasm

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Plasma Cell Neoplasm pipeline depth and focus of Indication therapeutics

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Key Players

1200 Pharma LLC
2Seventy Bio Inc
3D Medicines Inc
AbbVie Inc
Abcuro Inc
AbelZeta Inc
ABL Bio Inc
Actinium Pharmaceuticals Inc
Adicet Bio Inc
AevisBio Inc
AKSO Biopharmaceutical Inc
Alabama Drug Discovery Alliance
Aleta Biotherapeutics Inc
Allife Medical Science and Technology Co Ltd
Allogene Therapeutics Inc
Alphamab Oncology
Ambrx Biopharma Inc
Amgen Inc
Amsterdam UMC
location VUmc
Antaimmu BioMed Co Ltd
Antengene Corp Ltd
Antion Biosciences SA
APO-T BV
Apollomics Inc
Arcellx Inc
Arcus Biosciences Inc
Ariz Precision Medicine Inc
Arjuna Therapeutics
Arovella Therapeutics Ltd
Artiva Biotherapeutics Inc
Ascentage Pharma Group International
Asclepius Technology Company Group Suzhou Co Ltd
Aslan Pharmaceuticals Ltd
AstraZeneca Plc
Asylia Therapeutics Inc
Auransa Inc
Aurigene Oncology Ltd
Austin Biosciences Corp
Auxi Therapeutics Sdn Bhd
Avecho Biotechnology Ltd
Bantam Pharmaceutical LLC
Bayer AG
Baylor College of Medicine
BeiGene Ltd
Beijing Jingda Biotechnology Co Ltd
Beijing Mabworks Biotech Co Ltd
Beijing StarMab BioMed Technology Ltd
Bellicum Pharmaceuticals Inc
Betta Pharmaceuticals Co Ltd
BeyondSpring Inc
BioCurate Pty Ltd
Biohaven Ltd
Biolexis Therapeutics Inc
Biosceptre International Ltd
BioTheryX Inc
BioVie Inc
Bivictrix Therapeutics PLC
Bold Therapeutics Inc
Bristol-Myers Squibb Co
BRL Medicine Inc
Calgent Biotechnology Co Ltd
CARsgen Therapeutics Ltd
Cartesian Therapeutics Inc
Case Comprehensive Cancer Center
Cell Source Inc
Cellectar Biosciences Inc
Cellenkos Inc
Cello Therapeutics Inc
Celularity Inc
Ceptur Therapeutics Inc
CGeneTech (Suzhou China) Co Ltd
Charite University Hospital of Berlin
Cheetah Cell Therapeutics Co Ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Chimeric Therapeutics Ltd
China Immunotech (Beijing) Biotechnology Co Ltd
Chinook Therapeutics Inc
Chong Kun Dang Pharmaceutical Corp.
Circio Holding ASA
Compugen Ltd
Convalife
CRISPR Therapeutics AG
Curocell Inc
Cyclacel Pharmaceuticals Inc
CytoMed Therapeutics Ltd
Cytovia Holdings Inc
Dana-Farber Cancer Institute Inc
Diverse Biotech Inc
ExCellThera Inc
F. Hoffmann-La Roche Ltd
Fera Pharmaceuticals LLC
Flavocure Biotech LLC
Fred Hutchinson Cancer Research Center
Galapagos NV
Galileo Research srl
Genenta Science SpA
Genentech USA Inc
Geron Corp
Gilead Sciences Inc
Ginkgo BioWorks Inc
GluBio Therapeutics Inc
GlycoMimetics Inc
Glycostem Therapeutics BV
Glykos Finland Oy
GlyTR Therapeutics Inc
GP Pharm SA
Gracell Biotechnologies Inc
GSK plc
GT Biopharma Inc
Guangzhou Bio-gene Technology Co Ltd
Guangzhou Diqi Pharmaceutical Technology Co Ltd
H. Lee Moffitt Cancer Center & Research Institute Inc
HaemaLogix Pty Ltd
Harbour BioMed (Guangzhou) Co Ltd
Hebei Senlang Biotechnology Co Ltd
Heinrich-Heine University
Helix BioPharma Corp
Helocyte Biosciences Inc
Hepion Pharmaceuticals Inc
Hinova Pharmaceuticals Co Ltd
HK inno.N Corp
Holy Stone Healthcare Co Ltd
HRAIN Biotechnology Co Ltd
Hualan Genetic Engineering Co Ltd
Huazhong University of Science & Technology
Hummingbird Bioscience Pte Ltd
I-Mab
iCamuno Biotherapeutics Co Ltd
iCell Gene Therapeutics LLC
IDAC Theranostics Inc
IDP Discovery Pharma SL
IGM Biosciences Inc
Immix BioPharma Inc
ImmuneCyte Inc
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
ImmunoAct Pvt Ltd
Immunophage Biotech Co Ltd
Immunotech Biopharm Ltd
Immunwork Inc
Incyte Corp
Indiana University School of Medicine
Inflection Biosciences Ltd
Inmune Bio Inc
Instituto de Biomedicina de Sevilla
Intellia Therapeutics Inc
Inventiva SA
IO Biotech Inc
Io Therapeutics Inc
Ionova Life Science Co Ltd
Istesso Ltd
Iterion Therapeutics Inc
Jiangsu Chai Tai Fenghai Pharmaceutical Co Ltd
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Pacific Meinuoke Bio-Pharmarceutical Co Ltd
Jiangsu Simcere Pharmaceutical Co Ltd
Jiangsu University Affiliated Hospital
JN Biosciences LLC
Johnson & Johnson
JSK Therapeutics Inc
Jubilant Therapeutics Inc
Juventas Cell Therapy Ltd
KAHR medical Ltd
Kartos Therapeutics Inc
Karyopharm Therapeutics Inc
Kelonia Therapeutics Inc
KeyMed Biosciences Inc
Kirilys Therapeutics Inc
Kite Pharma Inc
Klyss Biotech Inc
Kodikaz Therapeutic Solutions Inc
Komipharm International Co Ltd
Kunming Medical University
KYAN Therapeutics Inc
Lantern Pharma Inc
Legend Biotech Corp
Les Laboratoires Servier SAS
Leukogene Therapeutics Inc
Ligand Pharmaceuticals Inc
Lokon Pharma AB
Lotus Pharmaceutical Co Ltd
Loxo Oncology Inc
Luye Pharma Group Ltd
Mablink Bioscience SAS
Machavert Pharmaceuticals LLC
Marker Therapeutics Inc
Max Biopharma Inc
Max Delbruck Center for Molecular Medicine
MediGene AG
Meditope Biosciences Inc
MedPacto Inc
MedTherapy Biotechnology Inc
Memorial Sloan Kettering Cancer Center
Merck & Co Inc
Millennium Pharmaceuticals Inc
Miltenyi Biomedicine GmbH
MimiVax LLC
MiNK Therapeutics Inc
Monte Rosa Therapeutics Inc
MorphImmune
Morphogenesis Inc
MorphoSys AG
Multitude therapeutics Inc
Mustang Bio Inc
Mycovia Pharmaceuticals Inc
Nanexa AB
Nanjing Bioheng Biotech Co Ltd
Nanjing IASO Biotherapeutics Co Ltd
National Cancer Institute US
Nectin Therapeutics Ltd
Neomics Pharmaceuticals LLC
Neonc Technologies Inc
NewBay Medical Technology Co Ltd
NGM Biopharmaceuticals Inc
Northlake International LLC
Northwestern University
NovAb Inc
Novartis AG
Novassay SA
Ohio State University
OncoFusion Therapeutics Inc
OncoLife Therapeutics Pty Ltd
Oncolyze Inc
OncoMyx Therapeutics Inc
Onconova Therapeutics Inc
OncoPep Inc
Oncopeptides AB
OncoTherapy Science Inc
One World Cannabis Ltd
Ontario Institute for Cancer Research
Opna Bio SA
Orgenesis Inc
Oricell Therapeutics (Shanghai) Co Ltd
Osaka University
Otsuka Pharmaceutical Co Ltd
Panbela Therapeutics Inc
Paras Biopharmaceuticals Finland Oy
Pennsylvania State University
PentixaPharm GmbH
Peter MacCallum Cancer Centre
Pfizer Inc
Phi Pharma SA
PI Therapeutics Ltd
Pimera Inc
Pinotbio Inc
Prescient Therapeutics Ltd
Protheragen Inc
QLi5 Therapeutics GmbH
Quadriga BioSciences Inc
Qwixel Therapeutics LLC
Radboud University
RAPT Therapeutics Inc
RE-Stem Biotech Co Ltd
Recordati SpA
Regeneron Pharmaceuticals Inc
Remd Biotherapeutics Inc
Reverb Therapeutics Inc
Salarius Pharmaceuticals Inc
Sana Biotechnology Inc
Sanofi
SELLAS Life Sciences Group Inc
Shanghai GeneChem Co Ltd
Shanghai Henlius Biotech Inc
Shanghai HyaMab Biotech Co Ltd
Shanghai Institute of Materia Medica Chinese Academy of Sciences
Shanghai Junshi Biosciences Co Ltd
Shanghai Novamab Biopharmaceuticals Co Ltd
Shanghai Pudong Hospital
Shanghai Simnova Biotechnology Co Ltd
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
Shanghai YaKe Biotechnology Co Ltd
Shenzhen Geno-Immune Medical Institute
Shenzhen Neptunus Institute of Pharmaceutical Technology Co Ltd
Shenzhen Second People's Hospital
Shenzhen Targetrx Inc
Shilpa Biologicals Pvt Ltd
Shuttle Pharmaceuticals Holdings Inc
Sichuan Huiyu Pharmaceutical Co Ltd
SignPath Pharma Inc
Simcere Pharmaceutical Group Ltd
Sino-American Cancer Foundation
SooChow University
Sorrento Therapeutics Inc
Sound Biopharmaceuticals
Sphaera Pharma Pte Ltd
Starton Therapeutics Inc
Stemline Therapeutics Inc
SteroTherapeutics LLC
Sumitomo Dainippon Pharma Oncology
Inc
SUNY Upstate Medical University
Sutro Biopharma Inc
Suzhou JiSheng Pharmaceutical Co Ltd
Synactix Pharmaceuticals Inc
SynDevRx Inc
T-CURX GmbH
TaiRx Inc
Takeda Pharmaceutical Co Ltd
Targazyme Inc
TC BioPharm Ltd
Telix Pharmaceuticals Ltd
TEZCAT Laboratories LLC
The Cleveland Clinic Foundation
The First Affiliated Hospital of Nanjing Medical University
The Walter and Eliza Hall Institute of Medical Research
Theolytics Ltd
TheraBioPharma Inc
TiCARos Co Ltd
Transgene Biotek Ltd
TRIGR Therapeutics Inc
Triterpenoid Therapeutics Inc
Triumvira Immunologics Inc
TTY Biopharm Co Ltd
UAB Minority Health and Health Equity Research Center
University Medical Center Hamburg-Eppendorf
University Medical Center Utrecht
University of Alabama
University of Bradford
University of California Los Angeles
University of Connecticut
University of Maryland School of Medicine
University of Sheffield
University of Texas Health Science Center at San Antonio
University of Wollongong
Up Therapeutics Inc
UTC Therapeutics Inc
Vanda Pharmaceuticals Inc
VaxCell Biotherapeutics Co Ltd
Vaxil Bio Therapeutics Ltd
Verastem Inc
Vichem Chemie Research Ltd
Vincerx Pharma Inc
Virtuoso Therapeutics Inc
Vycellix Inc
Washington University School of Medicine
Wellington Zhaotai Therapies Ltd
WindMIL Therapeutics Inc
Window Therapeutics Inc
Wistar Institute
Wuhan YZY Biopharma Co Ltd
Wurzburg University Hospital
XBiotech Inc
Xbrane Biopharma AB
Xencor Inc
Xi'An Yufan Biotechnology Co Ltd
Xiangxue Life Sciences
XNK Therapeutics AB
Xuzhou Medical College

Frequently asked questions

Currency USD
$2,000

Can be used by individual purchaser only

Most Popular
$4,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Plasma Cell Neoplasm reports
Pharmaceuticals
New
New Drug Approvals and Their Contract Manufacture - 2024 Edition
$4,995 | April 2024
Pharmaceuticals
New
Methicillin-Resistant Staphylococcus aureus (MRSA) Epidemiology Analysis and Forecast to 2033
$3,995 | April 2024
Pharmaceuticals
New
Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products,…
$6,995 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Plasma Cell Neoplasm – Drugs In Development, 2023 in real time.

  • Access a live Plasma Cell Neoplasm – Drugs In Development, 2023 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more